{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:55:11Z","timestamp":1788263711397,"version":"build-2803163510"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"\n Importance<\/jats:title>\n The wide use of unregulated cannabidiol (CBD) products among consumers raises safety concerns. Most research on CBD has studied the relatively high doses used by patients taking prescription CBD. However, limited safety data are available at lower doses.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To study the effects of 4-weeks of twice-daily CBD use on the liver and endocrine hormones using a dose within the range consumers are taking with unregulated CBD products.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This randomized double-blinded placebo-controlled trial from January to August 2024, using per protocol analysis, included healthy adults recruited from a clinical pharmacology unit (Spaulding Clinical Research in West Bend, Wisconsin).<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Healthy participants were randomized to CBD, 5 mg\/kg\/d (2.5 mg\/kg\/d twice daily), or placebo for 28 days with weekly laboratory assessments.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary end point was the percentage of participants with an alanine aminotransferase or aspartate aminotransferase level elevation greater than 3 times the upper limit of normal during the study.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n In 201 healthy participants (median age, 36 years [IQR, 30-43 years]; 89 women [44%]), 8 participants (5.6%; 95% CI, 1.8%-9.3%) in the CBD group and 0 participants (0%; 95% CI, 0%-7.6%) in the placebo group had liver enzyme level elevation greater than 3 times the upper limit of normal. Seven participants met withdrawal criteria for potential drug-induced liver injury, detected at day 21 in 2 participants and day 28 in 5 participants. No differences in change from baseline were observed between the CBD and placebo groups for total testosterone and inhibin B in male participants or thyrotropin, total triiodothyronine, and free thyroxine in all participants.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this study, the incidence of elevated alanine aminotransferase or aspartate aminotransferase coupled with the finding of increased eosinophilia, underscores the need for further investigation on the long-term effects of CBD use, its impact on various populations, and the safety of lower doses commonly used by consumers.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT06192589<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.2366","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:00:49Z","timestamp":1751886049000},"page":"1070","source":"Crossref","is-referenced-by-count":33,"title":["Cannabidiol and Liver Enzyme Level Elevations in Healthy Adults"],"prefix":"10.1001","volume":"185","author":[{"given":"Jeffry","family":"Florian","sequence":"first","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Salcedo","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Burkhart","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aanchal","family":"Shah","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi Manasa S.","family":"Chekka","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dro","family":"Keshishi","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"},{"name":"Now with Nurix Therapeutics, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShanChao","family":"Yang","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"},{"name":"Now with Los Angeles General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Fein","sequence":"additional","affiliation":[{"name":"Spaulding Clinical Research, West Bend, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"DePalma","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murali","family":"Matta","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"},{"name":"Now with Merck, Lansdale, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Strauss","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"},{"name":"Now with Translational Cures, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Rouse","sequence":"additional","affiliation":[{"name":"Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"12","key":"ioi250038r1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.47373","article-title":"Past-year use prevalence of cannabidiol, cannabigerol, cannabinol, and ?8-tetrahydrocannabinol among US adults.","volume":"6","author":"Wilson-Poe","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"9","key":"ioi250038r2","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1111\/add.16519","article-title":"Changes in self-reported cannabis use in the United States from 1979 to 2022.","volume":"119","author":"Caulkins","year":"2024","journal-title":"Addiction"},{"key":"ioi250038r3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.copsyc.2021.03.005","article-title":"Trends over time in adult cannabis use: A review of recent findings.","volume":"38","author":"Hasin","year":"2021","journal-title":"Curr Opin Psychol"},{"key":"ioi250038r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100253","article-title":"Prevalence of and trends in current cannabis use among US youth and adults, 2013-2022.","volume":"12","author":"Mattingly","year":"2024","journal-title":"Drug Alcohol Depend Rep"},{"issue":"6","key":"ioi250038r5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1111\/bph.14943","article-title":"Trends in use, pharmacology, and clinical applications of emerging herbal nutraceuticals.","volume":"177","author":"Williamson","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"20","key":"ioi250038r7","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1001\/jama.2022.20620","article-title":"Closing the loophole on hemp-derived cannabis products: a public health priority.","volume":"328","author":"Harlow","year":"2022","journal-title":"JAMA"},{"issue":"6","key":"ioi250038r9","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/joim.13627","article-title":"Cannabidiol-associated hepatotoxicity: a systematic review and meta-analysis.","volume":"293","author":"Lo","year":"2023","journal-title":"J Intern Med"},{"issue":"8","key":"ioi250038r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.20603","article-title":"Efficacy and safety of cannabidiol plus standard care vs standard care alone for the treatment of emotional exhaustion and burnout among frontline health care workers during the COVID-19 pandemic: a randomized clinical trial.","volume":"4","author":"Crippa","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"ioi250038r12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s42238-021-00061-5","article-title":"Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems.","volume":"3","author":"Moltke","year":"2021","journal-title":"J Cannabis Res"},{"key":"ioi250038r13","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2024.1356009","article-title":"Cannabidiol usage, efficacy, and side effects: analyzing the impact of health conditions, medications, and cannabis use in a cross-sectional online pilot study.","volume":"15","author":"Binkowska","year":"2024","journal-title":"Front Psychiatry"},{"issue":"1","key":"ioi250038r14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1159\/000531666","article-title":"Long-term, self-dosing CBD users: indications, dosage, and self-perceptions on general health\/symptoms and drug use.","volume":"6","author":"Kaufmann","year":"2023","journal-title":"Med Cannabis Cannabinoids"},{"issue":"2","key":"ioi250038r15","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/j.1439-0272.1991.tb02520.x","article-title":"Quantitative evaluation of spermatogenesis in mice following chronic exposure to cannabinoids.","volume":"23","author":"Patra","year":"1991","journal-title":"Andrologia"},{"issue":"1","key":"ioi250038r16","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/0041-008X(81)90122-8","article-title":"Toxicity of short-term administration of cannabinoids to rhesus monkeys.","volume":"58","author":"Rosenkrantz","year":"1981","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"ioi250038r17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/0748233709354553","article-title":"Testicular toxicity in cannabis extract treated mice: association with oxidative stress and role of antioxidant enzyme systems.","volume":"26","author":"Mandal","year":"2010","journal-title":"Toxicol Ind Health"},{"key":"ioi250038r18","first-page":"419","article-title":"Effects of marihuana inhalation on spermatogenesis of the rat.","volume":"22-23","author":"Huang","year":"1978","journal-title":"Adv Biosci"},{"issue":"3","key":"ioi250038r19","first-page":"299","article-title":"Testicular degeneration and necrosis induced by chronic administration of cannabis extract in dogs.","volume":"69","author":"Dixit","year":"1977","journal-title":"Endokrinologie"},{"key":"ioi250038r20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1335441","article-title":"Product labeling accuracy and contamination analysis of commercially available cannabidiol product samples.","volume":"15","author":"Gidal","year":"2024","journal-title":"Front Pharmacol"},{"key":"ioi250038r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109522","article-title":"Cannabidiol (CBD) product contamination: Quantitative analysis of ?9-tetrahydrocannabinol (?9-THC) concentrations found in commercially available CBD products.","volume":"237","author":"Johnson","year":"2022","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"ioi250038r23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ajg.2016.517","article-title":"ACG clinical guideline: evaluation of abnormal liver chemistries.","volume":"112","author":"Kwo","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"ioi250038r26","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100289","article-title":"Prevalence of cannabidiol use and correlates in US adults.","volume":"13","author":"Choi","year":"2024","journal-title":"Drug Alcohol Depend Rep"},{"issue":"5","key":"ioi250038r27","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1002\/cpt.2071","article-title":"Cannabidiol and abnormal liver chemistries in healthy adults: results of a phase I clinical trial.","volume":"109","author":"Watkins","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"Pt A","key":"ioi250038r28","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.106938","article-title":"Abrupt withdrawal of cannabidiol (CBD): a randomized trial.","volume":"104","author":"Taylor","year":"2020","journal-title":"Epilepsy Behav"},{"key":"ioi250038r29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2024.104073","article-title":"Evaluation of the efficacy, safety, and pharmacokinetics of nanodispersible cannabidiol oral solution (150 mg\/mL) versus placebo in mild to moderate anxiety subjects: A double blind multicenter randomized clinical trial.","volume":"97","author":"Gundugurti","year":"2024","journal-title":"Asian J Psychiatr"},{"issue":"9","key":"ioi250038r30","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1177\/0960327113512860","article-title":"Female gender as a susceptibility factor for drug-induced liver injury.","volume":"33","author":"Amacher","year":"2014","journal-title":"Hum Exp Toxicol"},{"issue":"7","key":"ioi250038r31","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study.","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"ioi250038r32","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1530\/eje.0.1470255","article-title":"Evidence for functional CB1 cannabinoid receptor expressed in the rat thyroid.","volume":"147","author":"Porcella","year":"2002","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"ioi250038r33","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1080\/07853890310004084","article-title":"Inhibin B: a novel marker of spermatogenesis.","volume":"35","author":"Pierik","year":"2003","journal-title":"Ann Med"},{"issue":"5","key":"ioi250038r34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.9740\/mhc.2023.10.217","article-title":"Consumer perception, knowledge, and uses of cannabidiol.","volume":"13","author":"Nguyen","year":"2023","journal-title":"Ment Health Clin"},{"issue":"2","key":"ioi250038r35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/alcalc\/agn099","article-title":"Biomarkers of liver status in heavy drinkers, moderate drinkers and abstainers.","volume":"44","author":"Alatalo","year":"2009","journal-title":"Alcohol Alcohol"},{"key":"ioi250038r36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/1471-230X-12-145","article-title":"Effects of coffee, smoking, and alcohol on liver function tests: a comprehensive cross-sectional study.","volume":"12","author":"Jang","year":"2012","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"ioi250038r37","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","article-title":"Interactions between cannabidiol and commonly used antiepileptic drugs.","volume":"58","author":"Gaston","year":"2017","journal-title":"Epilepsia"},{"key":"ioi250038r38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.seizure.2020.09.010","article-title":"Interaction of cannabidiol with other antiseizure medications: a narrative review.","volume":"86","author":"Gilmartin","year":"2021","journal-title":"Seizure"},{"issue":"4","key":"ioi250038r39","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.3390\/ijms25042370","article-title":"The role of cannabidiol in liver disease: a systemic review.","volume":"25","author":"Chen","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"12","key":"ioi250038r40","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1111\/jgh.16730","article-title":"Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review.","volume":"39","author":"Eadie","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"ioi250038r41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3928\/00989134-20210610-02","article-title":"Cannabidiol (CBD) use by older adults for acute and chronic pain.","volume":"47","author":"Porter","year":"2021","journal-title":"J Gerontol Nurs"},{"key":"ioi250038r6","volume-title":"Background materials for the June 14, 2022, meeting of the Science Board to the FDA","author":"Food and Drug Administration","year":"2022"},{"key":"ioi250038r8","volume-title":"Cannabidiol (Epidiolex) prescribing information","author":"Food and Drug Administration","year":"2018"},{"key":"ioi250038r11","volume-title":"Consumer insights report 2023","author":"Brightfield Group","year":"2023"},{"key":"ioi250038r22","unstructured":"US Food and Drug Administration. Collection of race and ethnicity data in clinical trials. October 26, 2016. Accessed June 2, 2025. https:\/\/www. fda.gov\/media\/75453\/download"},{"key":"ioi250038r24","unstructured":"Food and Drug Administration. Guidance for industry: drug-induced liver injury: premarketing clinical evaluation. July 2009. Accessed April 4, 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/drug-induced-liver-injury-premarketing-clinical-evaluation"},{"key":"ioi250038r25","unstructured":"US Dept of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. November 17, 2017. Accessed May 29, 2025. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2836267\/jamainternal_florian_2025_oi_250038_1756399031.24166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T15:01:19Z","timestamp":1756825279000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2836267"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":41,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.2366","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}